In our study, we clearly showed a 1.8% mutation rate of high penetrance genes, with 1.4% from BRCA1 and 0.5% from BRCA2 (Table 2), concealed in non-high-risk breast cancer patients, who needed alternations in management during their ongoing healthcare. The gene discussed is BRCA2; the disease is breast carcinoma.